Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

ement;

 "Broker Projected

Earnings Per Share"

the median of earnings per share forecasts made by the brokers named in theSources and Bases section that published revised earnings per share forecasts

following the announcement of the Tysabri Transaction on February 6, 2013 and prior

to the Proposal Announcement;

 "Broker Projected

EBITDA"

the median of EBITDA forecasts made by the brokers named in the Sources and Bases

section that have published revised EBITDA forecasts following the announcement of

the Tysabri Transaction on February 6, 2013 and prior to the Proposal Announcement;

 "Broker Projected

Revenue"

the median of revenue forecasts made by the brokers named in the Sources and

Bases section that have published revised revenue forecasts following the

announcement of the Tysabri Transaction on February 6, 2013 and prior to the

Proposal Announcement;

 "Current Enterprise

Value"

the enterprise value of Elan as at February 15, 2013, calculated by Royalty Pharma in

accordance with Appendix VI;

 "Disposed Tysabri

Interest"

the interest in Tysabri that will be sold by Elan to Biogen upon the completion of the

Tysabri Transaction;

 "Disposed Tysabri

Percentage"

the percentage of the economic value of  the Pre-Restructuring Tysabri Participation

that will be sold by Elan to Biogen upon the completion of the Tysabri Transaction;

 "Disposed Tysabri

Percentage Range"

46 percent to 54 percent, being the range that Royalty Pharma has used for the

preparation of its illustrative calculation of the value of the residual Tysabri Royalty;

 "Elan" or "the Company"

Elan Corporation plc;

 "Elan ADS's"

Elan American Depository Shares, each representing one (
'/>"/>

SOURCE RP Management, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
2. Cowen Healthcare Royalty Partners Raises $1 Billion
3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
6. AVANIR Pharmaceuticals To participate in two conferences in March
7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Three Lawrence Livermore ... Hydrogen Production R&D Award for their ... water using sunlight. , Shared with collaborators from ... University of Nevada, Las Vegas (UNLV), the award ... of photoelectrochemical solar-hydrogen production and corrosion processes. , ...
(Date:8/28/2014)... August 28, 2014 SPIE Fellow Glenn ... and Optical Science and Director of the Center for ... Carolina at Charlotte, and co-founder and Chairman of the ... as the 2015 Vice President of SPIE, the international ... Philip Stahl announced recent election results at the Annual ...
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
(Date:8/28/2014)... Aug. 28, 2014  Next month, executives from clinical trial ... industry events beginning with Patient-Centered Clinical Trials 2014 , ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits of ... of tactics – from media to mobile apps – can ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3BBK Worldwide Leads Sessions at Key September Events 2
... Webcast on Wednesday, June 17 at 8:30 a.m. Eastern Time ... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced today ... and Drug Administration (FDA) recommended by a vote of ... uricase enzyme, be granted marketing approval by the FDA for ...
... ... in a dynamic and unpredictable world at Wharton Leadership Conference. , ... Philadelphia, PA (Vocus) June 16, 2009 -- As the ... is well-positioned to deliver dynamic innovations to meet the evolving markets demand because “change is ...
... , , - Dosimetry Study Results Show Greater ... Normal Organs - , , - All Patients in the ... Time for Recurrent GBM Patients - , , TORONTO and ... PPHM ) today reported that researchers will present data at the ...
Cached Biology Technology:FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 3FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 4Leading for Growth in the New Economic Reality Includes Vision and Innovation 2Leading for Growth in the New Economic Reality Includes Vision and Innovation 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 6
(Date:9/1/2014)... Conventional wisdom has long held that corals ... reefs are passive organisms that rely entirely ... as nutrients and oxygen. But now scientists at ... in Israel have found that they are far ... into turbulent patterns that greatly enhance their ability ...
(Date:9/1/2014)... (September 1, 2014, 10:20 AM EDT) It may ... low-calorie foods over unhealthy higher-calorie foods, according to new ... Nutrition Research Center on Aging (USDA HNRCA) at Tufts ... in the journal Nutrition & Diabetes , a ... that it is possible to reverse the addictive power ...
(Date:9/1/2014)... electron microscopy revealed the presence of tiny blob-like structures ... scientists still don,t know what they do even ... to be crucial to the life of a cell, ... treatment., In the Journal of Cell Biology , ... various backgrounds, from biophysics to cell biology, to focus ...
Breaking Biology News(10 mins):Nature's tiny engineers 2Nature's tiny engineers 3Training your brain to prefer healthy foods 2Scientists call for investigation of mysterious cloud-like collections in cells 2
... scientists have received new funding for a research program ... economically feasible. The project is based on the serendipitous ... fish cages in Puerto Rico by the thousands. The ... fascinating habits such as their tendency to crawl in ...
... mussels and oysters are important vehicles for the ... undercooked. Vibrio species, including human pathogens, are particularly ... even after cleaning procedures, thus representing a potential ... are well known to affect the persistence of ...
... during the summer in Alaska waters, is one of the ... in the 1800s has now left us with only a ... different species from right whales seen in the North Atlantic ... areas and ecological parameters critical to the survival of this ...
Cached Biology News:New project aims to make large-scale lobster farms feasible 2New project aims to make large-scale lobster farms feasible 3Edible bivalves as a source of human pathogens: signals between vibrios and the bivalve host. 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
... is for 2-D separations. The cell has a ... II xi multi-cell can be customized for several ... and cooling system. The PROTEAN II xi multi-cell ... XL multi-cell for a wider format that accommodates ...
... depletion cocktail is tailored to ... suspensions of rat spleen cells. ... StemSep (or compatible 0.5 Tesla) ... T cell content of the ...
... 20 cm, is used for vertical slab gel ... gels. The cell is supplied without spacers and ... with gaskets, lower buffer chamber, lid with cables, ... upper buffer dam, casting stand with gaskets, leveling ...
...
Biology Products: